Loading…
← CockpitCompetitor Analysis › DSFIR.AS DSM-Firmenich AGOpen in the cockpit ↗

DSM-Firmenich AGDSFIR.ASCompetitor analysis, valuation and peers

Netherlands · EUR·Consumer Staples›Household/Personal Care

Swiss-Dutch maker of flavors, fragrances, and nutrition/health ingredients used by food, beverage, and personal-care brands worldwide.

≈ A larger International Flavors & FragrancesMomentum leader 92
Mkt cap
$27.5B
US dollars, full cap
Free float
87%
of shares outstanding
$/day
$68.9M
20-day average traded
Fwd P/E
28.6×
forward earnings
ROIC−WACC
-4.7 pp
WACC 6.5%
Hurdle
+21 pp
Req g minus delivered
Next earnings
92 days
18 Feb 2027
Close · EUR€104.75
1D+1.1%
1W-1.3%
1M-2.6%
3M+15.4%
6M+46.9%
YTD+52.3%
1Y+47.2%
ATR %2.6%
52w lowhigh7.7% off high

What DSM-Firmenich does

Swiss-Dutch maker of flavors, fragrances, and nutrition/health ingredients used by food, beverage, and personal-care brands worldwide.

Sells ingredients that go into customers' recipes and formulas, such as flavors, fragrance oils and vitamins, so a product specified once is typically reordered for years. Formed by the 2023 merger of Dutch DSM and Swiss Firmenich, it has been separating off its animal-nutrition business to concentrate on perfumery, taste and health ingredients.

In one line: A larger International Flavors & Fragrances.

Products and services

  • Taste & flavors
  • Fragrance & beauty ingredients
  • Health & nutrition ingredients
  • Animal nutrition

Customers

  • Nestle
  • Unilever
  • P&G
  • Food and beverage manufacturers

Where it sits in the supply chain

  • Specialty ingredients
  • Flavors, fragrances & nutrition
  • Ingredient formulation for consumer…

What could go right

  • Cross-selling post DSM-Firmenich merger
  • Health & wellness ingredient demand

What could go wrong

  • Merger integration costs
  • Input cost/raw material swings

Moat: narrow (scale, IP / patents, switching costs). Formulations are embedded in customers' recipes; reformulation is costly, but the category has scaled peers.

Headquarters: Kaiseraugst, Switzerland / Netherlands (dual) · Founded: 2023 · Employees: 28,550

Named competitors

DSM-Firmenich at a glance

Size DSM-Firmenich (DSFIR.AS) is a Netherlands Consumer Staples company (Household/Personal Care) with a market value of $27.5B, the 11th largest of 60 Netherlands companies the cockpit tracks. Shares closed at €104.75 on 18 Nov 2026.

Performance Over six months the shares gained 46.9%, against +15.0% for the median peer and -4.8% for the Netherlands market (cap-weighted) — 2nd highest of 18 in its peer set.

Growth Revenue fell 44.8% over the last twelve months (peer median +5.8%); the operating margin is 7.9% (peer median 15.0%).

Valuation It trades at 28.6× forward earnings against a peer median of 26.9× (8th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +21 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.7 points below its cost of capital (6.5% WACC).

Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014016021 May 202621 Aug 202618 Nov 2026DSFIR.AS 144Peer median 114
Six months, rebased to 100: DSM-Firmenich against the median of its 17 peers (local-currency closes).

DSM-Firmenich financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€7.19B€9.03B€9.05B€10.6B€8.39B
Revenue growth—0%-15%+27%—
Gross profit€3.29B€3.63B€3.69B€3.21B€2.78B
EBITDA€1.34B€1.61B€1.60B€1.31B€1.38B
Net income-€1.38B-€1.08B€250M-€652M€460M
Free cash flow€913M€790M€1.11B€719M€417M
Capital expenditure€689M€764M€764M€684M€644M
Total debtn/a€5.28B€5.28B€4.83B€3.06B

Quarterly statements and history in the cockpit →

DSM-Firmenich competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%0%+10%+20%CHD4452ELESSITY-ABEIGIVNRKTHINDUNILVRCLX8113MARICOPUIGKMB4911GODREJCPCLDABURDSFIR.AS6-month return →1-month return →
Up and to the right = strong over both horizons. DSM-Firmenich is the large dot.

Fundamentals: revenue growth against valuation

-40%-20%0%+20%20×40×CHD4452ESSITY-ABEIGIVNRKTHINDUNILVRCLX8113MARICO4911GODREJCPCLDABURDSFIR.ASRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. DSM-Firmenich is the large dot.

Capital: growth delivered against growth the price implies

0%+10%+20%+30%0%20%CHD4452ELESSITY-ABEIGIVNRKTHINDUNILVRCLXMARICOPUIGKMB4911GODREJCPCLDABURDSFIR.ASGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. DSM-Firmenich is the large dot.

DSM-Firmenich competitors and peer comparison

Head to head with its named competitors (DSFIR.AS vs GIVN.SW vs IFF vs SY1.DE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
DSM-Firmenich DSFIR.AS$27.5B+47%-45%8%28.6×23.7%
Givaudan GIVN.SW$44.7B+42%-2%18%34.0×11.2%
International Flavors & Fragrances IFF$20.1B+8%-17%11%22.7×17.9%
Symrise SY1.DE$14.2B+21%-1%12%24.8×7.9%

How DSM-Firmenich compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

DSM-Firmenich against its 17 peers (data as of 18 Nov 2026)
MeasureDSFIR.ASPeer medianRank in peer set
1-month return-2.6%+4.9%lowest of 18
6-month return+46.9%+15.0%2nd highest of 18
Distance from 52-week high-7.7%-3.7%9th lowest of 18
Revenue growth (TTM)-44.8%+5.8%lowest of 18
Operating margin7.9%15.0%2nd lowest of 18
Forward P/E28.6×26.9×8th most expensive of 18
Growth the price implies (Req g, 7 yrs)23.7%5.1%5th most demanding of 18
Growth delivered (Del g)+2.5%+4.4%6th lowest of 18
Hurdle (Req g minus delivered)+21.2 pp+5.9 pp2nd most demanding of 18
ROIC minus cost of capital-4.7 pp+6.7 pplowest of 18
EV / EBITDA22.2×16.1×7th most expensive of 18
Net debt / EBITDA3.3×1.4×2nd most indebted of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
DSM-Firmenich DSFIR.ASNetherlands$27.5B+47%-45%8%28.6×23.7%+2.5%
Church & Dwight CHDUnited States$26.4B+16%+2%18%28.1×7.7%+4.8%
Kao 4452.TJapan$22.7B+39%+6%10%25.6×1.5%+4.1%
Estée Lauder Companies (The) ELUnited States$37.7B+34%+6%13%29.4×16.2%-1.5%
Essity ESSITY-A.STSweden$19.3B+12%-2%12%15.6×-3.0%+2.6%
Beiersdorf BEI.DEGermany$18.8B+12%-2%12%21.3×-3.1%+7.0%
Givaudan GIVN.SWSwitzerland$44.7B+42%-2%18%34.0×11.2%+3.4%
Reckitt Benckiser RKT.LUnited Kingdom$47.5B+22%-2%28%16.7×2.1%+0.3%
Hindustan Unilever HINDUNILVR.NSIndia$50.0B-11%+6%21%41.4×27.4%+6.5%
Clorox CLXUnited States$13.1B+15%+6%14%18.9×4.1%-1.8%
Unicharm 8113.TJapan$13.0B+20%+2%11%26.9×0.1%+5.4%
Marico MARICO.NSIndia$12.6B+9%+20%16%52.2×28.3%+11.1%
Puig Brands PUIG.MCSpain$12.4B+31%+4%16%18.1×-2.6%+11.7%
Kimberly-Clark KMBUnited States$65.8B+11%-8%14%15.2×5.1%-3.0%
Shiseido 4911.TJapan$10.8B+47%+6%6%35.1×12.7%+1.0%
Godrej Consumer Products GODREJCP.NSIndia$9.75B-12%+12%18%39.1×32.9%+6.6%
Colgate-Palmolive CLUnited States$78.6B+9%+6%22%24.7×-4.9%+4.4%
Dabur India DABUR.NSIndia$7.16B-16%+9%15%31.8×27.4%+6.6%

Questions

Who are DSM-Firmenich's main competitors?
Named competitors: Givaudan (GIVN.SW), International Flavors & Fragrances (IFF), Symrise (SY1.DE). The cockpit's measured peer set (industry) also includes Church & Dwight (CHD), Kao (4452.T), Estée Lauder Companies (The) (EL), Essity (ESSITY-A.ST), Beiersdorf (BEI.DE), Givaudan (GIVN.SW).
Is DSM-Firmenich expensive compared with its peers?
On forward p/e it trades at 28.6× against a peer median of 26.9×, 8th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +21 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has DSM-Firmenich stock performed?
Over six months to 18 Nov 2026 the shares returned +46.9% against +15.0% for the median peer; over one year +47.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.